SOURCE: Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc.

July 09, 2015 08:30 ET

Stellar Biotechnologies Retains The Ruth Group to Advance Communications Objectives

PORT HUENEME, CA--(Marketwired - Jul 9, 2015) - Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), a leading provider of Keyhole Limpet Hemocyanin (KLH) protein, a crucial component for the development of many novel immunotherapies, today announced that it has retained New York City-based investor and public relations agency The Ruth Group as its strategic communications advisors.

"The Ruth Group has impressive knowledge of the life science sector, and more specifically immunotherapy, in such a way that we are confident in their ability to communicate our story to our investors, the media and scientific communities crucial to our growing success as a leading provider of the KLH protein," said Frank Oakes, Chairman, President and CEO of Stellar Biotechnologies. "We expect The Ruth Group to work with us as a trusted partner and we look forward to advancing our company further as a result of their anticipated guidance."

Stellar's relationship with TRG is effective immediately. The companies have agreed to a standard time and cash fee structure for services rendered. The Ruth Group will receive a fee of US $8,500 per month for a minimum of seven months through January 31, 2016. Stellar may cancel the agreement after the initial seven-month term upon 30 days written notice. TRG does not have any interest, directly or indirectly, in Stellar or our securities, or any right or intent to acquire such an interest in connection with the provision of the services or otherwise.

About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's, and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Visit www.stellarbiotech.com and the Stellar KLH knowledge base www.klhsite.org.

About The Ruth Group
Ruth Group (TRG) is a leading strategic communications firm focused exclusively on the healthcare industry. Founded in 1999, TRG provides investor and public relations counsel and services to a diverse group of innovative healthcare companies. TRG is laser-focused on life sciences and biotechnology, medical technology and tools/diagnostics, and healthcare services/HCIT. TRG's strong track record of success has been achieved through its breadth and depth of healthcare expertise, deep Wall Street relationships, integrated PR capabilities and comprehensive team approach.

Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; governmental regulations and the ability or failure to comply with governmental regulations; the timing of anticipated results; and other factors referenced in the Company's filings with securities regulators. For a discussion of further risks and uncertainties related to the Company's business, please refer to the Company's public company reports filed with the TSX Venture Exchange and the U.S. Securities and Exchange Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the information contained in this press release.

Contact Information

  • Stellar Biotechnologies Company Contact:
    Mark A. McPartland
    Vice President of Corporate Development and Communications
    Phone: +1 (805) 488-2800 ext. 103
    Email Contact
    www.stellarbiotech.com

    Investor Inquiries:
    Joseph A. Green
    The Ruth Group
    Phone: +1 (646) 536-7013
    Email Contact

    Media Inquiries:
    Melanie Sollid-Penton
    The Ruth Group
    Phone: +1 (646) 536-7023
    Email Contact